Evidence map›Paper›PMID 35649742›Full record

ArticleInternational journal of immunopathology and pharmacology

A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition.

Penghui Hu, Kaman So, Hongjie Chen, Qimou Lin, Meng Xu, Yiguang Lin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Penghui HuDepartment of Oncology, 162698The First Affiliated Hospital of Jinan University, Guangzhou, China.
Kaman SoDepartment of Oncology, 162698The First Affiliated Hospital of Jinan University, Guangzhou, China.
Hongjie ChenDepartment of Traditional Chinese Medicine, 144991Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Qimou LinDepartment of Surgery, 71537Jiangmen Central Hospital, Jiangmen, China.
Meng XuDepartment of Oncology, 162698The First Affiliated Hospital of Jinan University, Guangzhou, China.
Yiguang LinDepartment of Traditional Chinese Medicine, 144991Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0002-4637-9701
First Affiliated Hospital of Jinan University · CNJiangmen Central Hospital · CNSun Yat-sen University · CNUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CisplatinLung NeoplasmsAntibodies, MonoclonalDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFibroblast Growth Factor 2HumansAntibodies, MonoclonalCisplatinFibroblast Growth Factor 2basic fibroblast growth factor monoclonal antibodychemotherapycisplatin-resistanceepithelial-mesenchymal transitionNon-small cell lung cancer

Identifiers

PMID35649742
PMCPMC9168941
OpenAlexW4282926139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.